The estimated Net Worth of Brandi Roberts is at least $965 Tausend dollars as of 15 August 2023. Ms. Roberts owns over 20,000 units of Lineage Cell Therapeutics Inc stock worth over $17,304 and over the last 6 years she sold LCTX stock worth over $0. In addition, she makes $947,963 as Chief Financial Officer at Lineage Cell Therapeutics Inc.
Sign up
Ms. Roberts LCTX stock SEC Form 4 insiders trading
Brandi has made over 2 trades of the Lineage Cell Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 20,000 units of LCTX stock worth $5,000 on 15 August 2023.
The largest trade she's ever made was buying 20,000 units of Lineage Cell Therapeutics Inc stock on 15 August 2023 worth over $5,000. On average, Brandi trades about 2,778 units every 163 days since 2019. As of 15 August 2023 she still owns at least 20,000 units of Lineage Cell Therapeutics Inc stock.
You can see the complete history of Ms. Roberts stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brandi Roberts biography
Brandi Roberts serves as Chief Financial Officer of the Company. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial Officer at Mast Therapeutics, Inc. (MSTX), a publicly traded US-based biopharmaceutical company, from January 2013 to April 2017, having served as its Senior Vice President, Finance from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer. Ms. Roberts brings more than 24 years of public accounting and finance experience, including 21 years at publicly traded pharmaceutical, medical technology and life science companies to her position. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego. Ms. Roberts has served on the Board of Temple Therapeutics BV since November 2019. She also currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers.
What is the salary of Brandi Roberts?
As the Chief Financial Officer of Lineage Cell Therapeutics Inc, the total compensation of Brandi Roberts at Lineage Cell Therapeutics Inc is $947,963. There are no executives at Lineage Cell Therapeutics Inc getting paid more.
How old is Brandi Roberts?
Brandi Roberts is 46, she's been the Chief Financial Officer of Lineage Cell Therapeutics Inc since 2019. There are 15 older and 1 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.
What's Brandi Roberts's mailing address?
Brandi's mailing address filed with the SEC is 1751 RIVER RUN, SUITE 400, , FORT WORTH, TX, 76107.
Insiders trading at Lineage Cell Therapeutics Inc
Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley und Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.
What does Lineage Cell Therapeutics Inc do?
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
What does Lineage Cell Therapeutics Inc's logo look like?
Complete history of Ms. Roberts stock trades at Tff Pharmaceuticals Inc und Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc executives and stock owners
Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brandi Roberts,
Chief Financial Officer -
Brian M. Culley M.A., M.B.A.,
CEO, Pres & Director -
Brian Culley,
Chief Executive Officer, Director -
Chase Leavitt,
General Counsel and Corporate Secretary -
Brandi L. Roberts,
Consultant -
Angus Russell,
Independent Director -
Michael Mulroy,
Independent Director -
Stephen Farrell,
Independent Director -
Neal Bradsher,
Independent Director -
Don Bailey,
Independent Director -
Deborah Andrews,
Independent Director -
Gary Hogge,
Senior Vice President of Clinical & Medical Affairs -
Alfred Kingsley,
Chairman of the Board -
Alexandra Hernandez,
Sr. Director of Fin. & Controller -
Dr. Rami Skaliter,
Chief Exec. Officer of Cell Cure Neurosciences Ltd. -
William Annett,
Pres & CEO of OncoCyte Corp. -
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
Sr. VP of Clinical & Medical Affairs -
Dr. François Binette M.Sc., Ph.D.,
Sr. VP & Global Head of R&D -
George A. Samuel III, J.D.,
Gen. Counsel & Company Sec. -
Ioana C. Hone,
Director of Investor Relations -
Kevin L. Cook,
Chief Financial Officer -
George A. Iii Samuel,
General Counsel/Secretary -
Anula Jayasuriya,
-
Dipti Amin,
-
Neal C Bradsher,
Director -
Alexandra Hernandez,
Sr Director Finance/Controller -
Kevin Leon Cook,
Chief Financial Officer -
Jill Ann Howe,
Chief Financial Officer